Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination Versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects With Asthma
Brief Summary: The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in adolescents and adults (12 years of age and older) taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.

ADVAIR™ and FLOVENT™ are trademarks of the GlaxoSmithKline Group of Companies.


Options:
A: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol xinafoate; Assigned to Arm(s): N/A
B: Arm Label: ADVAIR 100/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 100/50mcg | Arm Label: ADVAIR 250/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 250/50mcg | Arm Label: ADVAIR 500/50mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR 500/50mcg | Arm Label: FLOVENT 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 100mcg | Arm Label: FLOVENT 250mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 250mcg | Arm Label: FLOVENT 500mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT 500mcg | Intervention Type: DRUG; Name: ADVAIR 100/50mcg; Assigned to Arm(s): ADVAIR 100/50mcg | Intervention Type: DRUG; Name: ADVAIR 250/50mcg; Assigned to Arm(s): ADVAIR 250/50mcg | Intervention Type: DRUG; Name: ADVAIR 500/50mcg; Assigned to Arm(s): ADVAIR 500/50mcg | Intervention Type: DRUG; Name: FLOVENT 100mcg; Assigned to Arm(s): FLOVENT 100mcg | Intervention Type: DRUG; Name: FLOVENT 250mcg; Assigned to Arm(s): FLOVENT 250mcg | Intervention Type: DRUG; Name: FLOVENT 500mcg; Assigned to Arm(s): FLOVENT 500mcg
C: Arm Label: Placebo MDPI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo MDPI | Arm Label: Fp MDPI 25 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate | Arm Label: Fp MDPI 50 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate | Arm Label: FS MDPI 50/12.5 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate/Salmeterol | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): Fp MDPI 25 mcg BID, Fp MDPI 50 mcg BID | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol; Assigned to Arm(s): FS MDPI 50/12.5 mcg BID | Intervention Type: DRUG; Name: Placebo MDPI; Assigned to Arm(s): Placebo MDPI
D: Arm Label: Fluticasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Arm Label: Fluticasone plus salmeterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone, Drug: montelukast, Drug: Fluticasone plus salmeterol | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast | Intervention Type: DRUG; Name: Fluticasone plus salmeterol; Assigned to Arm(s): Fluticasone, Fluticasone plus salmeterol, Montelukast

Answer: B